Ripped 250 - Royal Pharmaceuticals
Ripped 250 von Royal Pharmaceuticals ist eine 250 mg/ml-Mischung für die Forschung, die Testosteronpropionat (100 mg), Drostanolonpropionat (50 mg) und Trenbolonacetat (50 mg) enthält. Diese Kurzester-AAS-Kombination wurde für intramuskuläre Depotstudien entwickelt und wird in der Forschung zur Erforschung der Androgensignalisierung, der Stickstoffretention, der Erythropoese und der metabolischen Wirkungen eingesetzt. Nicht für die Anwendung beim Menschen oder in der Tiermedizin geeignet.
€ 69.00
Beschreibung
Ripped 250 – Royal Pharmaceuticals (Research-Grade AAS Blend)
Kategorie: Injectable Anabolic-Androgenic Steroid Blend (Research Only)
Marke: Königliche Pharmazeutika
Stärke: 250 mg/ml total (Test P 100 mg, Mast P 50 mg, Tren A 50 mg)
Verpacken: 10 × 1 ml ampoules
Herkunft: Vereinigtes Königreich
Preis: €69
Hinweis zur Verwendung: For laboratory and analytical research only — not for human or veterinary administration.
🧪 What is Ripped 250?
Ripped 250 is a fixed-combination injectable consisting of three short-acting anabolic–androgenic steroid esters:
- Testosterone Propionate – 100 mg
- Drostanolone Propionate (Masteron P) – 50 mg
- Trenbolone Acetate – 50 mg
Short-chain esters create rapid release from the intramuscular depot, making this blend suitable for research requiring frequent sampling intervals or tight control of androgen exposure.
🔬 Key Technical Characteristics
- Pharmacological class: Anabolic-androgenic steroids (AAS)
- Route: Intramuscular injection
- Ester types: Propionate (Test/Mast) and acetate (Tren)
- Approximate half-lives: Test P ~2 days, Mast P ~2 days, Tren A ~2–3 days
- WADA-Status: All components are prohibited at all times under “Anabolic Agents”.
🧬 Wirkmechanismus
Testosterone Propionate
- Esterified form of endogenous testosterone
- Promotes protein synthesis, nitrogen retention and erythropoiesis
- Aromatises to estradiol and converts to DHT
Drostanolone Propionate (Masteron P)
- DHT-derived androgen with no aromatisation
- Strong AR binding; low water-retention profile
- May exhibit mild anti-estrogenic action at receptor level
Trenbolone Acetate
- 19-nor testosterone derivative with extremely high AR affinity
- Does not aromatise; interacts with progesterone receptors
- Associated with strong anabolic effects and reduced glucocorticoid signalling
Together, these compounds produce additive or synergistic effects on androgen-mediated pathways while also accumulating their individual risk profiles.
📚 Research Overview
- Testosterone esters — studied extensively in hypogonadism, lean-mass changes, bone density and hematology.
- Drostanolone — historically investigated in hormone-responsive breast cancer; displays typical DHT-like androgenic behaviour.
- Trenbolone — widely documented in veterinary models; shows powerful anabolic, neuroendocrine, and metabolic effects.
Ripped 250 as a combined formulation lacks clinical trial data; research is based on extrapolation from individual components.
📈 Potential Research-Level Observations
- Enhanced protein synthesis and nitrogen retention
- Marked changes in red blood cell mass and hemoglobin
- Reduced fat mass and altered nutrient partitioning (trenbolone-related)
- Increased muscle density and tissue “hardness” in controlled models
These findings apply only to research settings and do not imply suitability for unsupervised use.
⚠️ Risk Profile & Possible Adverse Effects
Endocrine & Reproductive
- Suppression of LH/FSH and endogenous testosterone
- Testicular atrophy, reduced sperm count, infertility
- Virilisation and menstrual disruption in females
Cardiovascular & Metabolic
- Reduced HDL, increased LDL
- Hypertension, fluid retention (via testosterone)
- Increased risk of thrombotic or cardiovascular events
- Polycythaemia (elevated hematocrit)
Hepatic & Renal
- Potential hepatic strain despite being non-oral injectables
- Renal stress secondary to blood-pressure alteration
Neuropsychiatric
- Mood instability, irritability, anxiety
- Insomnia or reduced impulse control
Other
- Acne, seborrhoea, androgenic alopecia
- Injection-site pain or infection
- Gynecomastia risk due to testosterone aromatisation combined with trenbolone’s progestogenic action
🛑 Compliance & Regulatory Notice
- All three ingredients are controlled/prescription-only substances in many jurisdictions.
- WADA prohibits testosterone, drostanolone and trenbolone in- and out-of-competition.
- Analytical detection windows vary depending on dose and duration.
- This product is supplied strictly for laboratory and analytical research — not for therapeutic or recreational use.
📊 Tabelle der technischen Daten
| Parameter | Test P | Mast P | Tren A |
|---|---|---|---|
| Chemical class | Androgen / AAS | DHT-derived AAS | 19-nor AAS |
| Concentration (mg/ml) | 100 mg | 50 mg | 50 mg |
| Ester | Propionate | Propionate | Acetate |
| Aromatisation | Yes | No | No (progestogenic) |
| Halbwertszeit | ~2 days | ~2 days | ~2–3 days |
| Main receptor | AR, aromatase (indirect) | Androgen receptor | AR & progesterone receptors |
| WADA status | Prohibited | Prohibited | Prohibited |
For laboratory research only — not for human or veterinary use.
Es sind noch keine Bewertungen vorhanden.
